Yale Friday Newsletter – 10/19/12
By The Petrie-Flom Center It’s Friday again! Enjoy the Yale Friday Newsletter (edited for our readership), with lots of great items this week.
Bioethics
-
Read more: Yale Friday Newsletter – 10/19/12 -
Read more: FDA Reprimands Genentech for “Drastically Overstat[ing] the Efficacy of Tarceva” FDA Reprimands Genentech for “Drastically Overstat[ing] the Efficacy of Tarceva”
by Jonathan J. Darrow On October 3, 2012, the FDA’s Division of Professional Drug Promotion issued an untitled letter to Genentech in connection with its cancer drug Tarceva. Tarceva (erlotinib) was approved in 2004 for the treatment of non-small cell lung cancer, and has since been approved, in combination with Gemzar (gemcitabine), for the treatment…
-
Read more: Art Caplan: Many needlessly getting steroid injections for back pain Art Caplan: Many needlessly getting steroid injections for back pain
By Arthur Caplan In his latest MSNBC column, Art Caplan addresses a different angle of the fungal meningitis outbreak: Many needlessly getting steroid injections for back pain, bioethicist says The quest for relief from pain has now resulted in the deaths of 19 people and a total of 247 confirmed infections of fungal meningitis from…
-
Read more: Glenn Cohen on Medical Tourism Glenn Cohen on Medical Tourism
By The Petrie-Flom Center Check out this great summary piece in the Harvard Gazette discussing Glenn Cohen‘s work on medical tourism, including some audio of his recent lecture at the Radcliffe Institute.
-
Read more: Reporting Information about Clinical Trial Data: Passing the Torch from HHS to the FDA Reporting Information about Clinical Trial Data: Passing the Torch from HHS to the FDA
By Leslie P. Francis In 2007, motivated by concerns that pharmaceutical companies were not sharing negative data about what had been learned in clinical trials, Congress established enhanced reporting requirements. A series of articles published in January 2012 in the British Medical Journal demonstrates that data reporting remains deeply problematic, especially for industry-sponsored trials. (The…
-
Read more: PCSBI: Privacy and Progress in Whole Genome Sequencing PCSBI: Privacy and Progress in Whole Genome Sequencing
By Holly Fernandez Lynch Yesterday, President Obama’s Commission for the Study of Bioethical Issues released its fifth report: Privacy and Progress in Whole Genome Sequencing. I haven’t had a chance to digest it yet, but for now, just wanted to call it to everyone’s attention. The gist seems to be privacy, privacy, privacy. Here are the…
-
Read more: Upcoming Event: Human Rights and the Social Determinants of Health, November 1-2, 2012 at Northeastern University Upcoming Event: Human Rights and the Social Determinants of Health, November 1-2, 2012 at Northeastern University
Human Rights and the Social Determinants of Health Thursday, November 1, 2012, 1-5:30pm Friday, November 2, 2012, 12-1:30pm Northeastern University School of Law Dockster Hall 65 Forsyth Street, Boston The Program on Human Rights and the Global Economy (PHRGE) and the Program on Health Policy and Law at Northeastern University School of Law are hosting an…
-
Read more: Upcoming Event – Frank Miller on Placebo-Controlled Trials Before Informed Consent Upcoming Event – Frank Miller on Placebo-Controlled Trials Before Informed Consent
By The Petrie-Flom Center What were they thinking? Placebo-controlled trials before informed consent Franklin G. Miller, Ph.D., Department of Bioethics, National Institutes of Health October 25, 2012 – 4pm Shapiro Clinical Center JCRT 5A (East Campus), Beth Israel Deaconess Medical Center, Boston, MA Sponsored by the Program in Placebo Studies and the Therapeutic Encounter; Martinos Center for Biomedical Imaging; MGH; BIDMC Division of General Medicine and Primary Care;…
-
Read more: Art Caplan on Grace Lee Art Caplan on Grace Lee
By Arthur Caplan Unfortunately, these stories are like deja vu. In his most recent MSNBC commentary, Art Caplan emphasizes that we all have the right to refuse medical care, even if others disagree and even if it means death. Here’s his take: Opinion: Daughter has right to die against parents’ wishes When your time comes…
-
Read more: Incentives for Blood Donation Incentives for Blood Donation
Al Roth has an interesting post up today at his Market Design blog referencing some data on the crowding out effect, i.e., the idea that if you pay people for something that they are currently donating, altruists will be “crowded out” and you’ll end up with less of the thing that you need. It turns…